Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Conduit Pharmaceuticals Inc. (CDT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: CDT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.52% | Avg. Invested days 63 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.74M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 2.21 - 1560.00 | Updated Date 06/29/2025 |
52 Weeks Range 2.21 - 1560.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -255.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3484180 | Price to Sales(TTM) - |
Enterprise Value 3484180 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -55.41 | Shares Outstanding 952229 | Shares Floating 552357 |
Shares Outstanding 952229 | Shares Floating 552357 | ||
Percent Insiders 18.39 | Percent Institutions 3.63 |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc. was founded in [Founding Year] with a mission to develop and commercialize innovative pharmaceutical solutions. Key milestones include [Milestone 1], [Milestone 2], and the successful launch of [Product Name]. The company has evolved to focus on [Specific Therapeutic Areas].
Core Business Areas
- Pharmaceutical Development: Conduit Pharmaceuticals Inc. is primarily engaged in the research, development, and commercialization of novel drug candidates targeting unmet medical needs. This includes preclinical research, clinical trials, and regulatory submissions.
- Therapeutic Focus: The company concentrates its efforts on developing treatments for specific disease areas such as [Disease Area 1] and [Disease Area 2].
Leadership and Structure
Conduit Pharmaceuticals Inc. is led by a team of experienced professionals, including [CEO Name] as Chief Executive Officer and [Other Key Leader] in [Their Role]. The organizational structure is designed to foster innovation and efficient drug development.
Top Products and Market Share
Key Offerings
- Product Name 1: [object Object]
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory oversight, and a continuous demand for new treatments. It is a highly competitive landscape driven by scientific innovation and market access.
Positioning
Conduit Pharmaceuticals Inc. positions itself as an innovator in [Specific Niche within the industry], leveraging its proprietary technology and scientific expertise to develop differentiated therapies.
Total Addressable Market (TAM)
[object Object]
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced research and development team
- Focus on high-unmet medical needs
Weaknesses
- Limited product pipeline diversity
- Dependence on successful clinical trial outcomes
- Potential for significant capital requirements
Opportunities
- Expanding into new therapeutic areas
- Strategic partnerships and collaborations
- Growing demand for innovative therapies
Threats
- Intense competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations and generic competition
Competitors and Market Share
Key Competitors
- Competitor A US Stock Symbol
- Competitor B US Stock Symbol
- Competitor C US Stock Symbol
Competitive Landscape
Conduit Pharmaceuticals Inc. competes by focusing on niche therapeutic areas where it can establish a strong scientific and clinical advantage. Its disadvantages may include limited resources compared to larger pharmaceutical giants.
Major Acquisitions
[Acquired Company Name]
- Year: [Year]
- Acquisition Price (USD millions): [Price]
- Strategic Rationale: [Explain the strategic reasons behind the acquisition.]
Growth Trajectory and Initiatives
Historical Growth: Conduit Pharmaceuticals Inc.'s historical growth has been characterized by [Describe historical growth patterns, e.g., successful funding rounds, progression of pipeline candidates].
Future Projections: Future growth is projected to be driven by the successful advancement of its drug pipeline through clinical trials and subsequent commercialization.
Recent Initiatives: Recent initiatives include [List recent strategic initiatives, e.g., initiation of Phase X clinical trial for Product Y, new strategic partnerships].
Summary
Conduit Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on developing innovative therapies for unmet medical needs. Its strengths lie in its proprietary technology and experienced R&D team, while its weaknesses stem from its early-stage pipeline and significant capital requirements. The company has opportunities to grow through strategic partnerships and expanding its therapeutic reach, but must navigate threats from intense competition and regulatory challenges. Its success hinges on the effective advancement of its drug candidates through clinical development and successful commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings if publicly traded)
- Industry reports
- Financial news outlets
- Company website
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. Financial data for Conduit Pharmaceuticals Inc. may be limited if the company is not publicly traded or is in its early stages of development. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.